Lupin launches Lapatinib Tablets
1st Oct 2020

Lupin has launched Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma received final approval for its ANDA from the United States Food and Drug Administration (USFDA). Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation. Lapatinib Tablets (RLD: Tykerb) had annual sales of approximately $61 million in the U.S. (IQVIA MAT June 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.